TargeGen Announces Successful Completion of Phase I Clinical Trial of Topical AMD Drug TG100801
SAN DIEGO, Feb. 27, 2007 /PRNewswire/ -- TargeGen, Inc. has announced that the Company has completed a single-center Phase I clinical trial of TG100801 in 42 healthy volunteer subjects. TG100801 is a small molecule, topically applied (eye drop), multi-target kinase inhibitor that is being developed for the treatment of macular degeneration and other debilitating diseases of the eye. Preliminary results from this Phase I study suggest that TG100801 is well tolerated in humans at the low and high doses tested when applied topically twice daily for 14 days. Final study results are expected by the end of April 2007. TargeGen currently plans to initiate Phase II clinical trials in wet age-related macular degeneration (AMD) patients in mid-2007.
TG100801, applied daily in eye drop form, is designed to suppress disease related edema, angiogenesis and inflammation simultaneously. Edema, angiogenesis and inflammation are pathological hallmarks of AMD, diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Currently approved therapies for macular degeneration require repeated injection into the eye.
"The successful completion of this 'first in human' safety study with TG100801 represents a meaningful milestone for TargeGen and sets the stage for the near term initiation of human efficacy trials. We remain very optimistic about the potential for demonstrating efficacy in humans in the near future," stated Peter G. Ulrich, President, CEO and Co-Founder of TargeGen.
About TargeGen, Inc.
TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen is developing novel small molecule therapeutics to treat certain diseases involving vascular leakage, vascular proliferation, inflammation, and hematological malignancies by targeting certain biochemical processes associated with the formation and repair of blood vessels and vascular permeability (edema).
TargeGen, which initiated operations in 2002, has raised more than $70M from top tier venture capital sources.
CONTACT: Peter G. Ulrich, President & CEO of TargeGen, Inc.,+1-858-678-0760, or fax, +1-858-678-0762, email@example.com
Web site: http://www.targegen.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2007